Monoclonal antibody · Agonist of CD137 (TNFRSF9) · developed by Adagene
ADG106 is a human agonistic monoclonal antibody targeting CD137 (4-1BB), a costimulatory receptor on T lymphocytes and natural killer cells. It activates CD137-mediated signaling to enhance T-cell proliferation, survival, and cytolytic activity, promoting anti-tumor immune responses. ADG106 is studied in HER2-negative breast cancer, advanced solid tumors, and non-Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05275777 | Phase 1/2 | HER2-negative Breast Cancer | Active not recruiting | ADAG |
| NCT04775680 | Phase 1/2 | Solid Tumor | Terminated | ADAG |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorHER2-negative Breast CancerNon Hodgkin LymphomaSolid Tumor
Updated Oct 3, 2026. Something wrong or missing? Report it on the ADAG page.
See ADAG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ADAG catalysts and pipeline →